Is there data supporting the omission of carboplatin from neoadjuvant TCHP therapy for HER2-positive breast cancer to reduce toxicity, particularly in light of findings from the KATHERINE study?

While there is no doubt that the inclusion of carboplatin increases the risk of hematologic and gastrointestinal (mainly diarrhea, but also more nausea) toxicities with TCHP, clinical trial results demonstrate that it also increases pathologic complete response (pCR) rates. No version of THP (using ...

It's a complicated issue. it is important to keep in mind that TRYPHAENA was a relatively small study with a primary endpoint of cardiac safety. It was not designed to investigate improvements in pCR rates. Furthermore the NEOSPHERE vs TRYPHAENA comparison compares 4 versus 6 cycles and thus, althou...